Terazosin Hydrochloride Capsule
Product Images NDC 71610-854

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Terazosin Hydrochloride (NDC 71610-854). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 0854 30)

Label for Terazosin Hydrochloride 1 mg capsules, supplied in a bottle containing 30 capsules. The label includes storage instructions to keep the product between 20-25 degrees Celsius and out of reach of children. It is labeled as Rx only and manufactured by Aphena Pharma Solutions - Tennessee, LLC in Cookeville, TN.*

FDA Label Image

Aphena (Aphena)

FDA Label Image

Terazosinhydrochloridechemicalstructure (Chemicalstructure)

Chemical structure of Terazosin Hydrochloride showing its molecular composition and arrangement, including the aromatic rings, nitrogen atoms, and other functional groups.*

FDA Label Image

Figure1 (Figure1)

Two line graphs showing clinical data for Terazosin compared to placebo over three months. The first graph depicts mean change in total symptom score from baseline, with Terazosin demonstrating a greater reduction than placebo. The second graph illustrates mean increase in peak flow rate (mL/sec) from baseline, where Terazosin shows a higher increase relative to placebo. Sample sizes for each group are noted.*

FDA Label Image

Figure2 (Figure2)

A line graph showing the mean change from baseline over a 30-month period. The x-axis represents time in months, marked at irregular intervals from 0 to 30. The y-axis represents the mean change from baseline, ranging approximately from 0 to -7. Data points are plotted and connected with lines, showing a decrease from 0 to about -5 by month 6, then fluctuating between -5 and -6 through month 30. Asterisks mark several points on the graph indicating statistical significance or notable data values.*

FDA Label Image

Figure3 (Figure3)

A line graph depicting mean change from baseline in mL/sec over a 30-month period. The X-axis represents months, ranging from 0 to 30, and the Y-axis shows the mean change from baseline in mL/sec, ranging from 0.0 to 4.5. Data points are connected by a line with markers, indicating general increase and stabilization after around 6 months, with several points marked by asterisks.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.